Histiocytosis
15
6
7
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
13.3%
2 terminated out of 15 trials
60.0%
-26.5% vs benchmark
7%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Histiocytosis in Injecting Drug Users
Histiocytic Disorder Follow-up Study
Molecular Targets for the Treatment of Histiocytosis
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Ceftriaxone in Non-neutropenic Fever
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders